| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 37.6 | 36.5 |
| Gross profit | 21.7 | 20.8 |
| Profit before tax | 4.5 | 3.4 |
| Net income | 3.2 | 2.3 |
| EPS (diluted, $ a share) | $0.15 | $0.11 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +39.7% |
|---|---|
| Revenue, year on year | +3.0% |
| Gross margin | 57.8% |
| Operating margin | 12.6% |
10-Q filed with the SEC, NYSE: INFU. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
InfuSystem Holdings, Inc: key numbers
- Share price
- $14.79Close, Nov 16
- Market cap
- $296M
- Shares outstanding
- 20.03MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from InfuSystem Holdings, Inc
All →InfuSystem Holdings Investor Presentation
InfuSystem Holdings, Inc. filed a formal investor presentation deck dated November 9, 2026, to provide a business update to investors. The presentation highlights the company's position as a home healthcare services platform and includes forward-looking statements regarding its growth initiatives and strategic partnerships.
InfuSystem Holdings Financial Results
InfuSystem Holdings reported Q3 2026 net revenues of $37.6 million, a 3% increase year-over-year, driven by strong growth in Oncology and Wound Care. Net income rose to $3.2 million, or $0.15 per diluted share, while Adjusted EBITDA margin expanded to 24.9%. The company reaffirmed its full-year 2026 guidance, expecting pro-forma revenue growth of 6% to 8%.
- Term
- Q3 2026
“We delivered another strong quarter, achieving record revenue of $37.6 million. After adjusting for the impact of the previously announced GE Healthcare contract restructuring, pro-forma revenue increased 10.2% compared to the prior-year period. Pro-forma growth has accelerated each quarter this year, up from 1.7% in the first quarter and 7.5% in the second quarter. We also increased Adjusted EBITDA by 12.5% and expanded Adjusted EBITDA margin to 24.9% from 22.8% in the prior-year period. These results reflect continued execution of our profitable growth strategy across our diversified operating platform.”
Carrie Lachance, Chief Executive Officer
“Growth during the quarter was driven by Oncology, where revenue grew 7.2%, and exceptional performance in Wound Care. Wound Care revenue increased $2.0 million, or 112%, compared to the prior-year period, including approximately $1.6 million of growth from our compression therapy product lines focused on lymphedema treatment.”
Carrie Lachance, Chief Executive Officer
InfuSystem Holdings Other 8-K Filing
InfuSystem Holdings, Inc. has postponed the release of its third quarter 2026 financial results to evaluate the accounting treatment of $4.2 million in ERP system implementation costs. The company is determining whether these costs should be capitalized and amortized over three years rather than expensed as incurred. Any resulting adjustment would be non-cash and would not impact the company's revenue or cash balances.